The present article confirmed that LXJDF could regulate the PI3K/Akt/mTOR pathway to intervene in psoriasis and dyslipidemia comorbidity by the experimental study of LXJDF on the IMQ-induced ApoE−/− mice model. This evidence concerns the gene AKT1 and metabolic syndrome.